Batten disease

Batten disease
ICD-10	E75.4
ICD-9	330.1
OMIM	204200
DiseasesDB	31534
MeSH	D009472

WikiDoc Resources for Batten disease
Articles
Most recent articles on Batten disease Most cited articles on Batten disease Review articles on Batten disease Articles on Batten disease in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Batten disease Images of Batten disease Photos of Batten disease Podcasts & MP3s on Batten disease Videos on Batten disease
Evidence Based Medicine
Cochrane Collaboration on Batten disease Bandolier on Batten disease TRIP on Batten disease
Clinical Trials
Ongoing Trials on Batten disease at Clinical Trials.gov Trial results on Batten disease Clinical Trials on Batten disease at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Batten disease NICE Guidance on Batten disease NHS PRODIGY Guidance FDA on Batten disease CDC on Batten disease
Books
Books on Batten disease
News
Batten disease in the news Be alerted to news on Batten disease News trends on Batten disease
Commentary
Blogs on Batten disease
Definitions
Definitions of Batten disease
Patient Resources / Community
Patient resources on Batten disease Discussion groups on Batten disease Patient Handouts on Batten disease Directions to Hospitals Treating Batten disease Risk calculators and risk factors for Batten disease
Healthcare Provider Resources
Symptoms of Batten disease Causes & Risk Factors for Batten disease Diagnostic studies for Batten disease Treatment of Batten disease
Continuing Medical Education (CME)
CME Programs on Batten disease
International
Batten disease en Espanol Batten disease en Francais
Business
Batten disease in the Marketplace Patents on Batten disease
Experimental / Informatics
List of terms related to Batten disease

Overview

Batten disease is a rare, fatal, inherited disease of the nervous system (neurodegenerative disorder) that begins in childhood. Also known as Spielmeyer-Vogt-Sjogren-Batten disease, it is the most common form of a group of disorders called neuronal ceroid lipofuscinosis (or NCLs). Although Batten disease is usually regarded as the juvenile form of NCL, some physicians use the term Batten disease to describe all forms of NCL.

Symptoms

Early symptoms of this disorder usually appear at age 4–10, with gradual onset of vision problems, including eye discoloration in a milky fog gloss over the eyes, or seizures. Early signs may be subtle personality and behavior changes, slow learning or regression, repetitive speech or echolalia, clumsiness, or stumbling. There may be slowing head growth in the infantile form, poor circulation in lower extremities (legs and feet), decreased body fat and muscle mass, curvature of the spine, hyperventilation and/or breath-holding spells, teeth grinding, and constipation.

Over time, affected children suffer mental impairment, worsening seizures, and progressive loss of sight, speech and motor skills. Eventually, children with Batten disease become blind, bedridden, and demented. Batten disease is often fatal by ages 8 to 15.

History

Batten disease is named after the British pediatrician Frederick Batten who first described it in 1903. Also known as Spielmeyer-Vogt-Sjogren-Batten disease, it is the most common form of a group of disorders called neuronal ceroid lipofuscinosis (or NCLs). Although Batten disease is usually regarded as the juvenile form of NCL, some physicians use the term Batten disease to describe all forms of NCL.

Inheritance and diagnosis

The disease is inherited in an autosomal recessive manner. The mutation causes the buildup of lipofuscins in the body's tissues. These substances consist of fats and proteins and form certain distinctive deposits that cause the symptoms and can be seen under an electron microscope. The diagnosis of Batten disease is based on the presence of these deposits in skin samples as well as other criteria. Six genes have now been identified that cause different types of Batten disease in children or adults; more have yet to be identified. Two of these genes encode enzymes. The function of most of these genes is still unknown. The identification of these genes opens up the possibility of gene replacement therapy or other gene-related treatments.

Treatment

In June 2004, a Phase I clinical trial was launched at Weill Medical College of Cornell University to study a gene therapy method for treatment of the signs and symptoms of late infantile neuronal ceroid lipofuscinosis (LINCL). The experimental drug works by delivering a gene transfer vector called AAV2CUhCLN2 to the brain.

In October 2005, the FDA approved the transplantation of fetal neuronal cells into the brains of children suffering from Infantile and Late Infantile versions of Batten disease. The cells, which are immature and in an early stage of development, are derived from aborted and miscarried fetuses and will be injected into the patient's brains. To avoid rejection of these foreign cells, the immune system of the patients has to be suppressed.

In November 2006, surgeons at Doernbecher Children's Hospital at Oregon Health & Science University began a clinical study in which purified neural stem cells were injected into the brain of a six year old child suffering from Batten disease, who had lost the ability to walk and talk. The patient is expected the first of six to receive the injection of a stem cell product from StemCells Inc., a Palo Alto biotech company. It is believed to be the first-ever transplant of fetal stem cells into a human brain.. By early December, the child had recovered well enough to return home and it was reported that there were some signs of speech returning. .

See also

• CLN3
• lysosomal storage disease

External links

• NCL resource - Batten disease at University College London
• Template:NINDS
• What is Batten disease at nataliefund.org
• Batten Disease and Research Association (bdsra.org)
• News of FDA approval at bdsra.org
• What is Batten? at lrbf.org